V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Bio-Rad Laboratories Executive Compensation (FY25)

BIO · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Norman Schwartz
Latest say-on-pay support
=
April 21, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Bio-Rad Laboratories brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 18, 2026Latest filing (8-K): April 24, 2026
8 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Bio-Rad Laboratories brief$1,500Get the executive brief
Velarion Member, one year
226 figures on this page: 222 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Norman Schwartz: $8,289,471 → $7,995,841 (3.5% lower)
CEO pay ratio: 108:1 → 97:1 (10.2% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Bio-Rad Laboratories' chief executive and what were they paid?
Norman Schwartz was paid $7,995,841 in total compensation as Chief Executive Officer and Chairman for fiscal 2025. Schwartz's total was 3.5% lower than the $8,289,471 reported for fiscal 2024.
What was Bio-Rad Laboratories' say-on-pay result?
The say-on-pay proposal drew 96.1% support at the meeting held April 21, 2026 for fiscal 2025.
Which companies are in Bio-Rad Laboratories' peer group?
Companies named in the disclosed peer group include Agilent Technologies Inc., Bruker Corporation, Charles River Laboratories, Inc., Dentsply Sirona, Inc. and Haemonetics Corporation, among others.
What is Bio-Rad Laboratories' chief executive pay ratio?
The company reported a chief executive pay ratio of 97:1 for fiscal 2025, against median employee compensation of $82,784.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Norman Schwartz
President, Chief Executive Officer and Chairman
◇—◇—◇—◇◇
Andrew Last
Executive Vice President Chief Operating Officer
◇—◇—◇—◇◇
Ilan Daskal
Executive Vice President and Chief Financial Officer
◇—◇—◇—◇◇
Dara Wright
Executive Vice President, President, Clinical Diagnostics Group
◇—◇—◇—◇◇
Simon May
Executive Vice President, President, Life Science Group
◇—◇—◇—◇◇
Michael Crowley
Executive Vice President, Global Commercial Operations
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Norman Schwartz
President, Chief Executive Officer and Chairman
◇—◇———◇◇
Andrew Last
Executive Vice President Chief Operating Officer
◇—◇———◇◇
Ilan Daskal
Former Executive Vice President and Chief Financial Officer
Departed during or after this year
◇—◇———◇◇
Dara Grantham Wright
Executive Vice President, President, Clinical Diagnostics Group
◇—◇———◇◇
Simon May
Executive Vice President, President, Life Science Group
◇—◇———◇◇
Michael Crowley
Executive Vice President, Global Commercial Operations
◇—◇———◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Norman Schwartz
Chief Executive Officer and Chairman
◇—◇◇◇—◇◇
Jonathan DiVincenzo
President and Chief Operating Officer
◇◇◇—◇—◇— not reconciled
Roop Lakkaraju
Executive Vice President, Chief Financial Officer
◇—◇—◇—◇◇
Michael Crowley
Executive Vice President, Global Commercial Operations
◇—◇◇◇—◇◇
Eva Engelhardt
Executive Vice President, President, Clinical Diagnostics Group
◇◇◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Norman Schwartz
Chief Executive Officer and Chairman
◇—◇◇◇—◇◇
Jonathan DiVincenzo
President and Chief Operating Officer
◇—◇◇◇—◇◇
Roop Lakkaraju
Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Rajat Mehta
Executive Vice President, Global Commercial Operations
◇—◇—◇—◇◇
James Barry
Executive Vice President and President, Life Science Group
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
James BarryOPTION◇——◇—◇◇
James BarryRSU◇——◇——◇
Jonathan P. DiVincenzoOPTION◇——◇—◇◇
Jonathan P. DiVincenzoRSU◇——◇——◇
Norman SchwartzRSU◇——◇——◇
Norman SchwartzOPTION◇——◇—◇◇
Rajat MehtaRSU◇——◇——◇
Rajat MehtaRSU◇——◇——◇
Roop K. LakkarajuRSU◇——◇——◇
Roop K. LakkarajuOPTION◇——◇—◇◇
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Norman SchwartzRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/3/2035
Option◇—◇3/8/2034
RSU◇◇——
Rajat MehtaRSU◇◇——
RSU◇◇——
James BarryOption◇—◇3/8/2034
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/3/2035
Jonathan DiVincenzoRSU◇◇——
Option◇—◇3/3/2035
RSU◇◇——
Roop LakkarajuRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/3/2035
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gregory K. Hinckley
Lead independent director
◇◇————◇
Melinda Litherland
◇◇————◇
Jeffrey L. Edwards
◇◇————◇
Arnold A. Pinkston
◇◇————◇
Allison Schwartz and Norman Schwartz served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agilent Technologies Inc. A
  • Bruker Corporation BRKR
  • Charles River Laboratories, Inc. CRL
  • Dentsply Sirona, Inc. XRAY
  • Haemonetics Corporation HAE
  • Hologic, Inc. HOLX
  • IDEXX Laboratories, Inc. IDXX
  • Illumina, Inc. ILMN
  • Integer Holdings Corporation ITGR
  • Integra LifeSciences Holdings Corporation IART
  • Lantheus Holdings LNTH
  • LivaNova PLC LIVN
  • Mettler-Toledo International Inc. MTD
  • Qiagen N.V. QGEN
  • QuidelOrtho Corporation QDEL
  • ResMed Inc. RMD
  • Revvity, Inc. RVTY
  • Sotera Health Company SHC
  • Steris Corporation STE
  • Teleflex Incorporated TFX
  • The Cooper Companies Inc. COO
  • Waters Corporation WAT
  • West Pharmaceutical Services, Inc. WST

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 21, 2026=◇◇◇
2022April 25, 2023=◇◇◇
2019April 28, 2020=◇◇◇
2016April 25, 2017=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Norman Schwartz (Chief Executive Officer and Chairman), FY2025 total compensation $7,995,841 (base salary $1,089,877) [exec_comp, SEC accession 0000012208-26-000020, filed 2026-03-25]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Bio-Rad Laboratories files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Bio-Rad Laboratories disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Bio-Rad Laboratories sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Bio-Rad Laboratories' disclosed peer group is defensible, who names Bio-Rad Laboratories back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
226 figures on this page: 222 cited to the filing that reported them, 4 calculated from figures it prints.
222 cited to the filing
4 calculated from the filing

Documents cited

  1. 0000012208-26-000024
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0000012208-26-000020
    DIRECTOR COMPENSATION · Director Compensation · GRANTS OF PLAN-BASED AWARDS TABLE · OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END · and 2 more sections
  3. 0001308179-25-000235
    SUMMARY COMPENSATION TABLE
  4. 0001308179-24-000313
    SUMMARY COMPENSATION TABLE
  5. 0000012208-23-000041
  6. 0001308179-23-000427
    SUMMARY COMPENSATION TABLE
  7. 0001193125-20-131076
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0000012208-17-000019
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Bio-Rad Laboratories executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/BIO (accessed 2026).
Short form: data: Velarion

The Bio-Rad Laboratories brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Bio-Rad Laboratories and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Bio-Rad Laboratories discloses

The companies named in BIO's own disclosed peer group.

Agilent Technologies Inc.Bruker CorporationCharles River Laboratories, Inc.Dentsply Sirona, Inc.Haemonetics CorporationHologic, Inc.IDEXX Laboratories, Inc.Illumina, Inc.Integer Holdings CorporationIntegra LifeSciences Holdings CorporationLantheus HoldingsLivaNova PLCMettler-Toledo International Inc.QuidelOrtho CorporationResMed Inc.Revvity, Inc.Sotera Health CompanySteris CorporationTeleflex IncorporatedThe Cooper Companies Inc.Waters CorporationWest Pharmaceutical Services, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy